132 related articles for article (PubMed ID: 29963201)
1. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.
Matsuda T; Takeuchi H; Sakurai T; Mayanagi S; Booka E; Fujita T; Higuchi H; Taguchi J; Hamamoto Y; Takaishi H; Kawakubo H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Oncol Lett; 2018 Jul; 16(1):1348-1356. PubMed ID: 29963201
[TBL] [Abstract][Full Text] [Related]
2. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
4. Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
Fukuda K; Funakoshi T; Sakurai T; Nakamura Y; Mori M; Tanese K; Tanikawa A; Taguchi J; Fujita T; Okamoto M; Amagai M; Kawakami Y
Melanoma Res; 2017 Aug; 27(4):326-334. PubMed ID: 28263240
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
6. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
Shimodaira S; Sano K; Hirabayashi K; Koya T; Higuchi Y; Mizuno Y; Yamaoka N; Yuzawa M; Kobayashi T; Ito K; Koizumi T
Vaccines (Basel); 2015 Dec; 3(4):1004-18. PubMed ID: 26690485
[TBL] [Abstract][Full Text] [Related]
7. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract][Full Text] [Related]
10. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
11. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
12. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based vaccine for pancreatic cancer in Japan.
Okamoto M; Kobayashi M; Yonemitsu Y; Koido S; Homma S
World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):133-8. PubMed ID: 26855819
[TBL] [Abstract][Full Text] [Related]
14. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
15. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
16. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
17. WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer.
Nagai H; Karube R
Cureus; 2023 Oct; 15(10):e47320. PubMed ID: 38022278
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2019 Jun; 23(3):279-288. PubMed ID: 31033141
[TBL] [Abstract][Full Text] [Related]
19. WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
Alzaaqi S; Naka N; Hamada K; Hosen N; Kanegae M; Outani H; Adachi M; Imanishi R; Morii E; Iwai M; Nakata J; Fujiki F; Morimoto S; Nakajima H; Nishida S; Tsuboi A; Oka Y; Sugiyama H; Oji Y
Oncol Lett; 2022 Feb; 23(2):65. PubMed ID: 35069874
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
